• Gardenuity

  Participated · Seed · Oct 2023

  Gardenuity operates a curated platform that pairs consumers and companies with customized gardens and gardening kits, using a patent-pending Match technology that factors weather, seasonality, farm inventory, plant nutrient needs and customer preferences. The company serves both consumers and corporate clients nationwide and has served over 500 companies, including customers such as Google and Cigna. Its core product is a combination of physical gardening kits and a digital experience that connects growers through a Digital Greenhouse Community. Gardenuity plans to enhance its technology platforms, expand its suite of gardens and kits, and grow its team across functions. The company will introduce Match 2.0—an improved version of its match technology—and expand its Digital Greenhouse Community to increase engagement and support. Founded in 2017, Gardenuity positions gardening as a wellness offering accessible regardless of age, location, circumstance, or skill level.

• LEXEO Therapeutics

  Participated · Series B · Sep 2021

  Lexeo Therapeutics is a genetic medicine company focused on transforming treatment for cardiovascular diseases and Alzheimer's. The company is advancing genetic-medicine clinical programs and intends to use new capital to fund those programs. Lexeo closed a $95M private placement, selling shares at $15.13 per share, and entered into a registration rights agreement. Proceeds are earmarked for clinical programs and general corporate purposes and are expected to extend the company's runway into 2027. The financing brings Lexeo's total capital raised to $180M. Lexeo was founded in 2018, is based in New York, and has between 11 and 50 employees. LEXEO Therapeutics is a New York City–based, clinical-stage gene therapy company advancing AAV-based gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease. The company’s pipeline targets both larger-rare and more prevalent patient populations and claims potential to address up to one million patients in the United States across diverse cardiomyopathies. LEXEO’s foundational science stems from partnerships and exclusive licenses with Weill Cornell Medicine and the University of California, San Diego. The company is led by experienced genetic-medicine and rare-disease drug-development executives and is advancing a deep and diverse portfolio of candidates. LEXEO is positioning its programs for further development and collaboration to move candidates through clinical development and toward commercialization. LEXEO Therapeutics is a fully integrated clinical-stage company advancing adeno-associated virus (AAV)-mediated gene therapies for genetic cardiovascular conditions and central nervous system diseases. Its pipeline includes lead programs LX2006 (IV gene therapy for cardiomyopathy associated with Friedreich’s ataxia), LX1004 (CNS-administered therapy for CLN2 Batten disease), and LX1001 (CNS-administered therapy for APOE4-associated Alzheimer’s disease). The company also recently acquired cardiac gene therapy programs and is developing additional preclinical programs focused on the genetics of Alzheimer’s disease (LX1020 and LX1021). LEXEO reports having more than 15 AAV-mediated gene therapy programs in research and development. Proceeds from its recent financing will support continued preclinical pipeline expansion and advancement of its lead programs through clinical development toward meaningful data catalysts. The company was founded on a gene therapy research legacy at Weill Cornell Medicine’s Department of Genetic Medicine. LEXEO Therapeutics is a New York City–based, fully integrated clinical-stage gene therapy company focused on adeno-associated virus (AAV)-mediated treatments. The company's core pipeline includes three clinical-stage programs: LX2006 (IV AAV frataxin therapy for cardiomyopathy in Friedreich’s ataxia; Phase 1 start planned for 2021), LX1004 (CNS AAV CLN2 therapy; Phase 1/2 completed) and LX1001 (CNS AAV APOE2 therapy for APOE4 homozygotes; Phase 1 ongoing). Clinical data published for LX1004 in Science Translational Medicine showed a single administration slowed CLN2 disease progression and was well tolerated over an 18-month study period. LEXEO’s preclinical portfolio spans monogenic, hereditary and acquired diseases and includes up to 15 additional potential AAV programs primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. The company intends to advance clinical programs through to commercialization while maintaining an ongoing research collaboration with Weill Cornell. LEXEO launched with an $85 million Series A to advance its lead investigational programs and is headquartered at the Alexandria Center for Life Science in New York City.

• Pepgen

  Participated · Equity · Aug 2021

  PepGen develops Enhanced Delivery Oligonucleotides (EDOs) to treat neuromuscular and neurologic diseases, using peptide-conjugated antisense oligonucleotides to improve delivery to multiple muscle tissues including cardiac tissue. Its lead DMD program, EDO51, aims to induce exon 51 skipping and is planned to enter Phase 1 trials in 2022; preclinical data suggest higher exon-skipping and dystrophin production at lower doses than existing therapies. The lead DM1 program, EDODM1, is designed to block toxic CUG repeats and is expected to enter clinical trials in early 2023. PepGen plans to expand its DMD program to additional exon-skipping populations and build a broader pipeline of oligonucleotide candidates for neuromuscular and neurologic diseases. The company is headquartered in Boston and will use recent proceeds to advance programs into the clinic and expand its team. Financially, PepGen announced an oversubscribed $112.5 million crossover financing following a $45 million Series A in December 2020. PepGen develops next-generation cell-penetrating peptides conjugated to phosphorodiamidate morpholino oligomers (PPMOs) to improve delivery and safety of oligonucleotide therapies. The platform is designed to enhance tissue distribution, notably achieving strong cardiac penetration unlike some competing approaches. Lead programs target Duchenne muscular dystrophy (DMD) and a pipeline of rare neuromuscular, neurologic, and primary cardiac conditions with severe cardiac manifestations. The company aims to advance its PPMO candidates into the clinic using the newly raised capital. PepGen emphasizes improved cellular uptake while engineering out prior safety signals associated with peptide delivery approaches. Its corporate headquarters will be in Boston while its research hub remains in the UK.

No current team members are available.